PentaMice



A Proprietary Set of Wildtype Mice Designed to Achieve Maximum Plasma Titers in Hybridoma Campaigns

Conventional immunization approaches utilized in hybridoma-based antibody discovery campaigns typically use one or two common wildtype (WT) mouse strains (e.g. Balb/c or C57Bl/6). LakePharma’s scientists have noted through a course of over 100 campaigns that this approach likely limits the identification of high-quality antibodies to just those target antigens that are efficiently processed and presented by a restricted major histocompatibility complex (MHC) repertoire.

LakePharma’s PentaMice™ Platform is a royalty-free set of mice comprising 5 WT strains that cover 9 distinct MHC haplotypes. A total of 10 mice (2 mice of each strain) are included in each set to achieve maximum plasma titers, thus boosting the opportunity to generate high-quality antibodies in vivo.


The Five Wildtype Strains in the PentaMice Platform


The Concept Behind the PentaMice Platform



Download a free eBook: Introduction to Hybridoma Technologies for Antibody Discovery

PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery webinar recording available NOW

Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW!

Download our Pentamice Flyer by clicking here


"LakePharma is nothing short of a true partner with Apollos Diagnostics. We will continue to work with LakePharma as a partner for all of our future antibody development campaigns."

- John Alderete, Ph.D., MBA; Founder and President of Folium Biomed, LLC
View the testimonial here

"LakePharma is a great partner to work with. Their expertise enables them to generate large panels of antibodies that can be used as the foundation for our therapeutic candidates"

Ronald Herbst, Ph.D., CSO, Pyxis Oncology

View Pyxis clinical pipeline

"LakePharma was a great partner; very helpful, focused, and committed. Thank you for your antibody engineering and production services which made this project a success."

- Maria Day, ImmuNext

View their press release here